The week in pharma: action, reaction and insight – week to June 14, 2024

By Barbara Obstoj-Cardwell. Editor

Last week Swiss ophthalmic disease drug developer Oculis Holdings announced positive top-line results from a Phase IIb study of its licaminlimab for the treatment of dry eye disease. On the regulatory front, Genfit and fellow French drugmaker Ipsen received US Food and Drug Administration (FDA) approval for their liver disease treatment Iqirvo (elafibranor). Additionally, the FDA granted approval of a new indication for Bristol Myers Squibb’s Augtyro in an aggressive blood cancer. Also of note last week, US pharma Pfizer had another setback for its Duchenne muscular dystrophy candidate fordadistrogene movaparvovec, as it missed Phase III endpoints.

Oculis’ licaminlimab shows solid signs of efficacy in dry eye